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Introduction: The seventh edition of the TNM Classification of
Malignant Tumors is due to be published early in 2009. In prepa-
ration for this, the International Association for the Study of Lung
Cancer established its Lung Cancer Staging Project in 1998. The
recommendations of this committee for changes to the T, N, and M
descriptors have been published. This report contains the proposals
for the new stage groupings.
Methods: Data were contributed from 46 sources in more than 19
countries. Adequate data were available on 67,725 cases of non-
small cell lung cancer treated by all modalities of care between 1990
and 2000. The recommendations for changes to the T, N, and M
descriptors were incorporated into TNM subsets. Candidate stage
groupings were developed on a training subset and tested in a
validation subset.
Results: The suggestions include additional cutoffs for tumor size,
with tumors7 cm moving from T2 to T3; reassigning the category
given to additional pulmonary nodules in some locations; and
reclassifying pleural effusion as an M descriptor. In addition, it is
suggested that T2b N0 M0 cases be moved from stage IB to stage
IIA, T2a N1 M0 cases from stage IIB to stage IIA, and T4 N0–1 M0
cases from stage IIIB to stage IIIA.
Conclusions: Such changes, if accepted, will involve a reassessment
of existing treatment algorithms. However, they are based on an
intensive and validated analysis of the largest database to date. The
proposed changes would improve the alignment of TNM stage with
prognosis and, in certain subsets, with treatment.
(J Thorac Oncol. 2007;2: 706–714)
The current (sixth) TNM Classification of MalignantTumours, introduced in 2002,1 made no changes to the
previous edition with regards to lung cancer. The proposals
with regard to lung cancer in the fifth edition, published in
1997,2 were based on a relatively small database of 5319
cases of non-small cell lung cancer (NSCLC) accumulated
since 1975. During this time, there had been many refine-
ments to the techniques available for clinical staging,
principally the routine use of computed tomography. The
database was largely from a single institution, containing
cases predominantly treated surgically. Repeated iterations
of the TNM Classification of Malignant Tumours had seen
the recommendations for lung cancer staging evolve with
little internal validation and no external validation of the
descriptors or the stage groupings. Increasingly reports
from other databases were challenging some of the de-
scriptors and suggesting revised stage groupings. The next
edition of the TNM Classification of Malignant Tumours,
the seventh, was due to be published early in 2007, now
2009. In preparation for this the International Association
for the Study of Lung Cancer (IASLC) established its Lung
Cancer Staging Project in 1998 to bring together the large
databases available worldwide and to form recommenda-
tions for the seventh edition that would be intensively
validated. The history of the project and details of the
database have been described elsewhere.3 The project has
been recognized by the International Union Against Can-
cer as the primary source for recommendations for revi-
sions to the sixth edition of the TNM Classification of
Malignant Tumours and has received funding from the
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American Joint Committee on Cancer to separately submit
proposals for its revision of the staging manual. The
recommendations of the staging committee have been
submitted to the International Union Against Cancer and
are shortly to be submitted to the American Joint Commit-
tee on Cancer.
METHODS
At a workshop held in London in February 2001, a
number of groups presented the data held in their institutions.
Our chosen biosciences partner, Cancer Research and Bio-
statistics, in discussion with the committee members, subse-
quently developed the data fields and dictionary. It was
decided that the study period should enlist cases diagnosed
between 1990 and 2000. This interval was chosen as it
represented a relatively short period during which staging
methods had been constant and allowed 5 years of follow-up
before analysis. Cases treated by all modalities of care,
including multimodality treatment, were included. From the
core of contributors who presented at the workshop, data
acquisition was widened to eventually involve 46 sources in
more than 19 countries. These additional sources were iden-
tified from the literature by their response to advertisements
in the journals or by contact from individual members of the
committee. A total of 100,869 cases were submitted to the
data center at Cancer Research and Biostatistics. After an
initial sift to exclude cases outside the study period, those for
whom cell type was not known, cases not newly diagnosed at
the point of entry, and those with inadequate information on
stage, treatment, or follow-up, 81,015 cases remained for
analysis. Of these, 67,725 were NSCLC and 13,290 were
small-cell lung cancer (SCLC). Only the NSCLC cases were
included in the analyses of the T, N, and M descriptors and
the subsequent analysis of TNM subsets and stage groupings.
Survival was measured from the date of entry (date of
diagnosis for registries, date of registration for protocols) for
clinically staged data and the date of surgery for pathologi-
cally staged data and was calculated by the Kaplan-Meier
method. Prognostic groups were assessed by Cox regression
analysis, using the SAS System for Windows Version 9.0
PHREG procedure.
Where the analyses showed descriptors to have a prog-
nosis that differed from the other descriptors in any T or M
category, two alternative strategies were considered: (1) Re-
tain that descriptor in the existing category, identified by
alphabetical subscripts. For example, additional pulmonary
nodules in the lobe of the primary, considered to be T4 in the
sixth edition,1 would become T4a, whereas additional pul-
monary nodules in other ipsilateral lobes, designated as M1 in
the sixth edition,1 would become M1a. (2) Allow descriptors
to move between categories, to a category containing other
descriptors with a similar prognosis, e.g., additional pulmo-
nary nodules in the lobe of the primary would move from T4
to T3, and additional pulmonary nodules in other ipsilateral
lobes would move from M1 to T4. The first strategy had the
advantage of allowing, to a large extent, retrograde compat-
ibility with existing databases. Unfortunately, this generated
a large number of descriptors (approximately 20) and an
impractically large number of TNM subsets (180). For this
reason, backward compatibility was compromised and strat-
egy (2) was preferred for its clinical utility. The resultant
TNM subsets and the numbers of cases in each subset by
clinical stage and pathologic stage are shown in Table 1. A
small number of candidate stage grouping schemes were
developed initially using a recursive partitioning and amal-
gamation algorithm.4 S-PLUS Version 7.0 was the statistical
software used to apply this algorithm and draw the initial tree.
The analysis grouped cases based on best stage (pathologic, if
available, otherwise clinical) after determination of best-split
points based on overall survival on indicator variables for the
newly proposed T/M categories and an ordered variable for N
category, excluding NX cases. This analysis was performed
on a randomly selected training set comprising two thirds of
the available data that met the requirements for conversion to
newly proposed T and M categories (n  17,726), reserving
9133 cases for later validation. The random selection process
was stratified by type of database submission and time period
of case entry (1990–1995 versus 1995–2000).
The recursive partitioning and amalgamation analysis
generated a tree-based model for the survival data using log
rank test statistics for recursive partitioning and, for selection
of the important groupings, bootstrap resampling to correct
TABLE 1. Total Number of International Database Cases
Classifiable According to Proposed TNM Stage Subsets for
Clinical Stage and Pathologic Stage
Clinical Stage
N Stage
Proposed T/M Stage N0 N1 N2 N3 Total
T1a 419 12 66 13 510
T1b 442 14 78 5 539
T2a 1345 71 326 39 1781
T2b 411 33 107 14 565
T3 2452 691 2355 616 6114
T4 144 17 134 44 339
M1a 213 41 220 157 631
M1b 626 221 1151 790 2788
Total 6052 1100 4437 1678 13,267
Pathologic Stage
N Stage
Proposed T/M Stage N0 N1 N2 N3 Total
T1a 1965 226 191 4 2386
T1b 1796 343 327 6 2472
T2a 3186 1123 905 18 5232
T2b 937 382 285 4 1608
T3 2188 1015 1114 74 4391
T4 224 118 217 12 571
M1a 99 42 94 4 239
M1b 15 7 11 5 38
Total 10,410 3256 3144 127 16,937
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for the adaptive nature of the splitting algorithm (Figure 1).
An ordered list of groupings from the terminal nodes of the
survival tree, with group sizes and hazard ratios, is shown in
Table 2. With this as a guide, several proposed stage group-
ings were created by combining adjacent groups. Selection of
a final stage grouping proposal from among the candidate
schemes was based on its statistical properties in the training
set and its relevance to clinical practice and was arrived at by
consensus.
RESULTS
The changes proposed to the current T and M descrip-
tors are highlighted in the full list of descriptors shown in
Table 3. These changes have been reported in detail in this
journal.5,6 The existing N descriptors were validated, and no
changes are proposed.7 The changes proposed suggest that
size cutoffs in addition to the 3-cm limit that separates T1
from T2 tumors be established. Tumors that fulfill the defi-
nition for T1 and are 2 cm in greatest dimension should be
designated T1a, whereas those that are 2 cm but 3 cm in
greatest dimension be designated T1b. Those tumors that
fulfill the present definition of T2 and are 5 cm in greatest
dimension become T2a, whereas those that are 5 cm but
7 cm in greatest dimension become T2b. Tumor dimen-
sion 7 cm becomes a T3 descriptor. Additional tumor
nodules in the lobe of the primary become T3, nodules in
other ipsilateral lobes become T4, whereas nodules in the
contralateral lung remain M1 disease. The presence of a
malignant pleural effusion, pleural dissemination, or peri-
cardial disease becomes an M descriptor. The M category
is subdivided into M1a, which includes the new descriptors
added to this category, i.e., cases with pleural nodules or
malignant pleural or pericardial effusion and additional
pulmonary nodules in the contralateral lung and M1b for
those cases with other distant metastases.
These proposed changes were incorporated into the
data and, after analysis of each TNM subset, the resultant
stage groupings were identified. These are summarized in
Table 4, in which are highlighted those TNM subsets that it
is proposed should move from their present stage grouping.
The moving of some cases from within a descriptor in the
present staging system to another in the proposals for the
seventh edition of the TNM classification and the creation of
new descriptors has led to the migration of certain TNM
subsets between stage groups. For example, of 1789 cases in
the database designated as T2 N1 M0 according to the sixth
edition, 400 were allocated to the new subset of T2b N1 M0
and another 205 migrate into the T3 N0 M0 subset. Conse-
quently, those cases remaining T2a N1 M0 had a survival
equivalent to that of stage IIA and not stage IIB as in the sixth
edition. The numbers driving this, and other changes, are
evident in Table 5. Those T2 tumors 5 cm but 7 cm in
greatest dimension are reclassified as T2b, and if node
negative migrate to stage IIA from stage IB. Those T2
tumors 7 cm in greatest dimension would become T3
tumors and move to stage IIB from IB if node negative and
to stage IIIA from IIB if associated with N1 disease. If
TABLE 2. Terminal Nodes from T/M and N Survival Tree,
Ordered by Hazard Ratio
Terminal Node Sample Size (Training Set) Hazard Ratio
T1a N0 1373 1.00
T1b N0 1257 1.28
T2a N0 2346 1.80
T2b N0 673 2.44
T1ab–T2ab N1 1460 2.72
T3 N0 2466 3.67
T1–2a N2 1253 3.67
T3 N1 1066 4.48
T4 N01 354 5.47
T2b N2 250 5.47
T3 N2 2006 6.69
M1a (N0–1) 301 7.39
T4 N2 239 7.39
M1a (N2) 212 9.97
T1-M1a N3 630 9.97
M1b (N0–1) 553 13.46
M1b (N2–3) 1287 16.44
Sample size is the number of cases in the training set classifiable by best stage.
FIGURE 1. Recursive partitioning and amal-
gamation–generated survival tree based on
best stage for 17,726 cases. T and M stages
(from proposed new T and M) are combined
as 0/1 indicators. N stage is ordered. The
number below each terminal node is the log
hazard ratio, with the T1aN0M0 category as
baseline.
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those cases with additional tumor nodules in the same lobe
as the primary are moved to T3 from T4 as proposed, then
such cases move from stage IIIB to IIB if node negative
and to stage IIIA if associated with N1 or N2 disease. The
changes to the T4 descriptor, the removal of cases with
additional tumor nodules in the lobe of the primary and
cases with pleural or pericardial disease, and the addition
of cases with additional tumor nodules in other ipsilateral
lobes result in a lower stage being assigned to most TNM
subsets containing the T4 descriptor. Those cases with
pleural or pericardial disease, if assigned to an M descrip-
tor, would consequently fall within stage IV disease.
Figures 2 and 3 show survival by stage according to the
sixth edition of TNM and by the newly proposed TNM stage
based on the entire set of cases available for reclassification.
(Cases without data on age, sex, and histology are excluded.)
Tables 6 and 7 show the statistics from Cox proportional
hazards regression modeling of the sixth edition of TNM and
the proposed new system for clinical and pathologic stage,
respectively. Stage was parameterized both as a set of indi-
cator variables and also by ordered variables (Tables 6 and 7),
adjusted for cell type, sex, region, and age (younger than 60
versus 60 and older).
The proposed system better delineates the early stage
cases, where problems with overlap between IB and IIA
have been noted with the sixth edition of TNM8 and are
clearly seen here on clinical staging. Improvement is also
seen in the distinction between clinical IIA and IIB, as well
as the proportion of cases assigned to stage IIA (a weak-
ness of the sixth edition of TNM).
For both the clinical and pathologic stage models, there
is an increase in the value for R2, an estimate of the percent-
age of variance explained by the model.9 The new system
makes use of well-justified changes to T and M and may
serve to identify subsets of patients with tumors of different
sizes with differing prognoses. Both the proposed new system
and the sixth edition of TNM yielded a reversal on pathologic
staging from the expected hazards for advanced stage disease
TABLE 3. Proposed Definitions for T, N, and M Descriptors
T (Primary Tumor)
TX Primary tumor cannot be assessed, or tumor proven by the
presence of malignant cells in sputum or bronchial
washings but not visualized by imaging or bronchoscopy
T0 No evidence of primary tumor
Tis Carcinoma in situ
T1 Tumor 3 cm in greatest dimension, surrounded by lung or
visceral pleura, without bronchoscopic evidence of
invasion more proximal than the lobar bronchus (i.e., not
in the main bronchus)a
T1a Tumor 2 cm in greatest dimension
T1b Tumor 2 cm but 3 cm in greatest dimension
T2 Tumor 3 cm but 7 cm or tumor with any of the following
features (T2 tumors with these features are classified T2a
if 5 cm)
Involves main bronchus, 2 cm distal to the carina
Invades visceral pleura
Associated with atelectasis or obstructive pneumonitis that
extends to the hilar region but does not involve the entire
lung
T2a Tumor 3 cm but 5 cm in greatest dimension
T2b Tumor 5 cm but 7 cm in greatest dimension
T3 Tumor 7 cm or one that directly invades any of the
following: chest wall (including superior sulcus tumors),
diaphragm, phrenic nerve, mediastinal pleura, parietal
pericardium; or tumor in the main bronchus 2 cm
distal to the carinaa but without involvement of the
carina; or associated atelectasis or obstructive
pneumonitis of the entire lung or separate tumor
nodule(s) in the same lobe
T4 Tumor of any size that invades any of the following:
mediastinum, heart, great vessels, trachea, recurrent
laryngeal nerve, esophagus, vertebral body, carina;
separate tumor nodule(s) in a different ipsilateral lobe
N (Regional Lymph Nodes)
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in ipsilateral peribronchial and/or ipsilateral hilar
lymph nodes and intrapulmonary nodes, including
involvement by direct extension
N2 Metastasis in ipsilateral mediastinal and/or subcarinal lymph
node(s)
N3 Metastasis in contralateral mediastinal, contralateral hilar,
ipsilateral or contralateral scalene, or supraclavicular
lymph node(s)
M (Distant Metastasis)
MX Distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis
M1a Separate tumor nodule(s) in a contralateral lobe; tumor with
pleural nodules or malignant pleural (or pericardial)
effusionb
M1b Distant metastasis
a The uncommon superficial spreading tumor of any size with its invasive compo-
nent limited to the bronchial wall, which may extend proximally to the main bronchus,
is also classified as T1.
b Most pleural (and pericardial) effusions with lung cancer are due to tumor. In a
few patients, however, multiple cytopathologic examinations of pleural (pericardial)
fluid are negative for tumor, and the fluid is nonbloody and is not an exudate. Where
these elements and clinical judgment dictate that the effusion is not related to the tumor,
the effusion should be excluded as a staging element and the patient should be classified
as T1, T2, T3, or T4.
TABLE 4. Descriptors, Proposed T and M Categories, and
Proposed Stage Groupings
Sixth Edition
T/M Descriptor
Proposed
T/M N0 N1 N2 N3
T1 (2 cm) T1a IA IIA IIIA IIIB
T1 (2–3 cm) T1b IA IIA IIIA IIIB
T2 (5 cm) T2a IB IIA IIIA IIIB
T2 (5–7 cm) T2b IIA IIB IIIA IIIB
T2 (7 cm) T3 IIB IIIA IIIA IIIB
T3 invasion IIB IIIA IIIA IIIB
T4 (same lobe nodules) IIB IIIA IIIA IIIB
T4 (extension) T4 IIIA IIIA IIIB IIIB
M1 (ipsilateral lung) IIIA IIIA IIIB IIIB
T4 (pleural effusion) M1a IV IV IV IV
M1 (contralateral lung) IV IV IV IV
M1 (distant) M1b IV IV IV IV
Cells in bold indicate a change from the sixth edition for a particular TNM category.
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(IIIB and IV). This result, although anomalous, can most
likely be explained by the nature of advanced-stage surgical
cases. By virtue of their expected resectability, they consisted
primarily of small effusions or additional nodules discovered
at surgery or of cases with single isolated central nervous
system or adrenal metastases.
In summary, the proposed system results in improved
R2 values for both clinical and pathologic stages, improved
separation between stages IIB and IIA for clinical and
pathologic stages, a more even distribution among the
stage groupings for both clinical and pathologic stages,
and an increase in the hazard ratio for stage when modeled
as an ordered variable. These advantages, combined with
enhanced clinical utility and incorporation of the refined T
and M criteria, make this system a strong candidate for a
revised staging system. The proposed stage groupings are
summarized in Table 8.
Validation
The proposals derived from the training set of 17,726
cases were internally validated against the validation set of
9133 cases. Details of these analyses are provided in the
companion paper on the validation process and results.10 In
brief, the validation set generated survival curves that were
generally similar to those in the training set and Cox propor-
tional hazards regression analyses that calculated the hazard
ratios between each pair of adjacent stage groups while
controlling for cell type, sex, age, and region were all statis-
tically significant using the pathologic staging data. There
were some nonsignificant differences in the early-staged
clinical cases, but this problem was present using both the
proposed system and the existing sixth edition of TNM and
may be the result of an unstable comparison as the validation
set contained only 3863 cases.
External validation was assessed against the Surveil-
lance, Epidemiology, and End Results Program database,
which records best stage and details of this comparison along
with survival curves are provided in our validation paper.10
The Surveillance, Epidemiology, and End Results Program
survival curves using the sixth edition of the TNM Classifi-
cation of Malignant Tumours and the IASLC proposed sys-
tem were compared. Generally, both the new system and the
existing performed well, but the separation between the IB
and IIA curves was better in the proposed system, whereas
the new IIA and IIB curves converged at 5 years.
DISCUSSION
Previous revisions to the TNM classification for lung
cancer contained very little internal and no external validation
information. In 1974, the second edition of the TNM Classi-
fication of Malignant Tumours 11 incorporated all of the
descriptors suggested by the American Joint Committee on
Cancer Task Force on Lung Cancer.12 Although T, N, and M
TABLE 5. Sample Sizes for TNM Subsets Providing the Basis for Proposed Changes T1–T3 by Best Stage, T4 by Best Stage,
and M1 by Best Stage
T1–T3 by Best Stage N0 N1 N2 N3
Sixth Edition
Descriptor
Proposed
T/M
Overall
Stage
Sample
Size
Overall
Stage
Sample
Size
Overall
Stage
Sample
Size
Overall
Stage
Sample
Size
T1 (2 cm) T1a IA 2134 IIA 242 IIIA 257 IIIB 19
T1 (2–3 cm) T1b IA 1902 IIA 360 IIIA 412 IIIB 13
T2 (5 cm) T2a IB 3547 IIB–>IIA 1184 IIIA 1198 IIIB 60
T2 (5–7 cm) T2b IB–>IIA 1016 IIB 400 IIIA 374 IIIB 20
T2 (7 cm) T3 IB–>IIB 457 IIB–>IIIA 205 IIIA 211 IIIB 5
T3 (invasion) IIB 3113 IIIA 1329 IIIA 2735 IIIB 642
T4 (same lobe nodules) IIIB–>IIB 174 IIIB–>IIIA 70 IIIB–>IIIA 127 IIIB 5
T4 by Best Stage N0–N1 N2–N3
Sixth Edition
Descriptor
Proposed
T/M
Overall
Stage
Sample
Size
Overall
Stage
Sample
Size
T4 (extension) T4 IIIB–>IIIA 432 IIIB 320
M1 (ipsilateral lung) IV–>IIIA 97 IV–>IIIB 86
M1 by Best Stage Any N
Sixth Edition
Descriptor
Proposed
T/M
Overall
Stage
Sample
Size
T4 (pleural dissemination) M1a IIIB–>IV 683
M1 (contralateral lung) IV 230
M1 (distant) M1b IV 2800
Cells in bold indicate a change from the sixth edition for a particular TNM category. Samples sizes for T/M descriptors are summarized across N-stage categories where possible
to highlight the decision points for the proposed stage groupings.
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categories were shown to have differing prognoses, there was
no validation presented to justify the individual descriptors.
In addition, of the 18 possible TNM subsets in that edition,
seven contained fewer than 100 cases, some as few as 24
cases, and four other subsets contained too few cases for any
analysis. In successive revisions, new descriptors were added
as deemed necessary. In some situations, as with additional
pulmonary nodules,2 these were added to existing T, N, and
M categories retaining the existing TNM stage subsets and
stage groupings. In other revisions, for example, the division
of T3 and T4 in the fourth edition,13 existing descriptors
were expanded and divided into new TNM subsets and
new stage groupings. Although changes in TNM subsets
and stage groupings were internally validated in a limited
way, there was no external validation presented and indi-
vidual descriptors were not validated. To a large extent,
the creation of new descriptors in earlier revisions and their
accommodation within the TNM classification for lung cancer
was driven largely by existing treatment algorithms.
The validation process has been an integral part of this
project. The internal and external validation of the T, N, and
M descriptors proposed by this project5–7 and that of the
TNM stage groupings suggested in this article will be pre-
sented in another article in this journal.10 Such intensive
validation has only been possible by the enormous size of the
database and the international spread of the contributions to
this project from the lung cancer community. This has,
however, led us to arrive at decisions that we recognize will
create problems for our colleagues in this field. The necessity
to sacrifice backward compatibility with existing databases in
the search for a staging system that is manageable in clinical
practice has already been mentioned. We further recognize
that moving some descriptors within stage categories and the
proposed changes to the stage groupings will cut across
established treatment algorithms. The moving of the larger,
node-negative T2 tumors (T2b cases 5 cm in greatest
dimension) and tumors 7 cm in greatest dimension (which
would become T3) from stage IB into stage IIA and stage IIB,
respectively, will clearly raise the question as to whether such
cases should have adjuvant chemotherapy after complete
resection. Although there is still doubt as to the value of
adjuvant chemotherapy after complete resection for node
negative cases in stage IB,14,15 at least two large trials have
shown a benefit for node-positive cases in stages II and
IIIA.16,17 The question as to whether these larger node-
negative tumors benefit from adjuvant therapy will only be
resolved by large, prospective, randomized trials. The reas-
signment of cases with additional nodules in an ipsilateral,
nonprimary tumor–bearing lobe into a T4 descriptor rather
than an M1 descriptor and the relocation of T4 N0 M0 and T4
N1 M0 cases into stage IIIA will also lead to questions as to
FIGURE 2. Overall survival, expressed as median survival
time (MST) and 5-year survival, by clinical stage using the
sixth edition of TNM (A) and proposed International Associa-
tion of the Study of Lung Cancer recommendations (B). FIGURE 3. Overall survival, expressed as median survival
time (MST) and 5-year survival, by pathologic stage using
sixth edition of TNM (A) and proposed International Associa-
tion of the Study of Lung Cancer recommendations (B).
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the appropriate treatment algorithm. The limitations of our
database do not allow us to be certain whether this reassign-
ment is appropriate for cases with multiple additional tumor
nodules or for all T4 cases. Multimodality treatment models,
some including surgery, will no doubt evolve, informed by
appropriate trials. In other situations, the changes suggested
for inclusion in the seventh edition of the TNM Classification
of Malignant Tumours might better reflect current practice as
with the move of cases with malignant pleural effusions into
an M category from a T category. Within our database, there
was a clear difference in prognosis between patients with
metastases to the ipsilateral pleura or contralateral lung and
those with metastases at distant sites outside the thorax. In
general, the latter have the worst prognosis and have been
historically considered as stage IV and candidates for primar-
ily systemic treatment. Within the cases proposed in an ex-
panded stage IV, there is still a prognostic difference between
those with spread within the thorax and those with metastases to
distant sites, and therefore differentiating between M1a and M1b
seems to be of relevance.
These recommendations have been based on the find-
ings of a large international database. The number of cases
recruited is 15 to 20 times larger than that which informed
any previous revision. Data have been donated by 46 sources
in 19 countries. We are all immensely grateful for the support
offered by colleagues around the world. Although the treat-
ment of these NSCLC cases included surgery in 53% of the
patients, there were 30% in which chemotherapy was used
and 29% in which radiotherapy was used. The data were
collected from cases treated over a relatively short period
during which the techniques used in clinical staging were
reasonably standardized worldwide. The recommendations
have been, for the first time, intensively validated. Internal
validation has ensured that the recommendations are sup-
ported by data from all geographic areas and across all types
of databases. External validation has been established against
the Surveillance, Epidemiology, and End Results Program
database.
There are, however, limitations to this project. The
volume of data and the international nature of the data
sources have made data audit extremely difficult, and, as a
result, only limited checks for consistency have been possi-
TABLE 6. Cox Proportional Hazards Regression Models for
the Sixth Edition of TNM and Proposed Clinical Stage
Groupings (IASLC)
Clinical Stage (Sixth Edition and IASLC Proposed) Modeled as
Indicator Variables
Hazard Ratio p
Comparisons Sixth Edition IASLC Sixth Edition IASLC
IB vs. IA 1.31 1.19 0.0001 0.0035
IIA vs. IB 1.35 1.23 0.1978 0.0020
IIB vs. IIA 1.20 1.46 0.4344 0.0001
IIIA vs. IIB 1.30 1.27 0.0001 0.0001
IIIB vs. IIIA 1.47 1.54 0.0001 0.0001
IV vs. IIIB 1.71 1.64 0.0001 0.0001
R2 25.86 26.77
Clinical Stage (Sixth Edition and IASLC Proposed) Modeled as
Ordered Variables
Hazard ratio p
Variable Sixth Edition IASLC Sixth Edition IASLC
Stage 1.36 1.38 0.0001 0.0001
Adjusted for cell type, sex, age, and region (n  11,536 (8944 events). IASLC,
International Association of the Study of Lung Cancer.
TABLE 7. Cox Proportional Hazards Regression Models for
the Sixth Edition TNM and Proposed Pathologic Stage
Groupings (IASLC)
Pathologic Stage (Sixth Edition and IASLC Proposed) as Indicator
Variables
Hazard Ratio p
Comparisons Sixth Edition IASLC Sixth Edition IASLC
IB vs. IA 1.72 1.55 0.0001 0.0001
IIA vs. IB 1.28 1.44 0.0001 0.0001
IIB vs. IIA 1.26 1.29 0.0002 0.0001
IIIA vs. IIB 1.48 1.47 0.0001 0.0001
IIIB vs. IIIA 1.27 1.79 0.0001 0.0001
IV vs. IIIB 0.91 0.86 0.2921 0.0974
R2 29.44 30.40
Pathologic Stage (Sixth Edition and IASLC Proposed) Modeled as
Ordered Variables
Hazard Ratio p
Variable Sixth Edition IASLC Sixth Edition IASLC
Stage 1.35 1.40 0.0001 0.0001
Adjusted for cell type, sex, age, and region (n  15,952 (8988 events). IASLC,
International Association of the Study of Lung Cancer.
TABLE 8. Proposed TNM Stage Groupings
Occult Carcinoma TX N0 M0
Stage 0 Tis N0 M0
Stage IA T1a, b N0 M0
Stage IB T2a N0 M0
Stage IIA T1a, b N1 M0
T2a N1 M0
T2b N0 M0
Stage IIB T2b N1 M0
T3 N0 M0
Stage IIIA T1, T2 N2 M0
T3 N1, N2 M0
T4 N0, N1 M0
Stage IIIB T4 N2 M0
Any T N3 M0
Stage IV Any T Any N M1a, b
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ble. There are glaring deficiencies in the global distribution of
the data with no data at all being included from Africa, South
America, or the Indian subcontinent. Other vast countries
such as Russia, China, and Indonesia are not represented or
only poorly represented. Although less surgically dominated
than previous databases, the spread of treatment modalities
does not reflect the practice in most institutions. The time
period under study predates the widespread and routine use of
positron emission tomography, which has had an enormous
impact on clinical staging algorithms. In any retrospective
database, one has to collect the data that was considered
important by each source, and this reflects the use for which
the data were collected. Although we have an enormous
amount of data on some descriptors, such as tumor dimen-
sion, we have too little on many to prove or disprove the
validity of some descriptors.
We hope that our colleagues in clinical practice will
recognize that the changes suggested by this project are
driven by the data available to us from a database of more
than 68,000 cases. Even with the acknowledged limitations of
the database, its breadth has allowed the application of
evidence-based standards in terms of statistical power, reli-
ability, and scientific validity that were not possible in pre-
vious revisions. Inevitably, existing treatment algorithms will
be challenged, but we hope by such rigorous analysis of large
volumes of data, the utility of the TNM classification for lung
cancer will be strengthened. It is our intention to ensure that
the expansion of the database, including the prospective
collection of data over the coming years, will ensure further,
carefully validated proposals concerning thoracic malignan-
cies for the eighth edition of the TNM Classification of
Malignant Tumours and beyond.
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